Thoracic Cancer最新文献

{"title":"Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1-Mediated DNA Damage Repair and PI3K/AKT Survival Signaling.","authors":"Jianghao Yu, Siyang Chen, Tingting Hou, Xianwu Weng, Yakun Liu, Junchao Huang, Zeshan Yang, Jinyu Bao, Changshuai Zhou, Wanqing Lv, Qingzhe Wu, Yun Xu, Jinshan Zhou","doi":"10.1111/1759-7714.70393","DOIUrl":"10.1111/1759-7714.70393","url":null,"abstract":"<p><p>Lung cancer remains a leading cause of cancer-related mortality worldwide, necessitating the development of novel therapeutic strategies. Matrine, a natural alkaloid derived from Sophora flavescens, has demonstrated broad antitumor properties, yet its underlying mechanisms, particularly concerning DNA damage response, remain incompletely elucidated. This study integrates network pharmacology, bioinformatics, and experimental validation to uncover a novel dual-targeting mechanism of matrine in lung cancer. Bioinformatics analysis identified CHEK1 as a key potential target. In vitro, matrine selectively inhibited proliferation, migration, invasion, and clonogenic survival of A549 and LLC cells, while reducing the G2/M phase proportion, indicating G2/M checkpoint impairment. Mechanistically, matrine concurrently downregulated CHEK1, p-PI3K, p-AKT, BCL-2, and EMT markers (Vimentin, MMP2, MMP9), and upregulated γH2AX, E-cadherin, Bax, and Cleaved Caspase-3. Crucially, siRNA experiments revealed that PI3K knockdown induced apoptosis without affecting CHEK1/γH2AX, whereas CHEK1 silencing promoted apoptosis independently of PI3K/AKT, demonstrating complementary. In vivo, matrine significantly inhibited LLC tumor growth in a xenograft model, suppressed proliferation (Ki67), and modulated the CHEK1-PI3K/AKT axis, corroborated by IHC and Western blotting. Importantly, matrine exhibited no significant systemic toxicity. Our findings unveil that matrine exerts potent antitumor effects by simultaneously inhibiting CHEK1-mediated DNA repair and PI3K/AKT survival signaling, presenting a novel dual-targeting approach for lung cancer treatment.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 18","pages":"e70393"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13597169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149025989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guiding the Application of Immunotherapy in Nonsmall Cell Lung Cancer: The Role of Biomarkers.","authors":"Yuting Sun, Xuelei Chu, Xinmiao Wang, Weina Li, Xiaoyu Zhu, Guanghui Zhu, Xinyi Ma, Xue He, Jie Li","doi":"10.1111/1759-7714.70342","DOIUrl":"10.1111/1759-7714.70342","url":null,"abstract":"<p><p>Although immunotherapy has completely transformed the treatment landscape of nonsmall cell lung cancer (NSCLC), its wide application is still limited by the heterogeneity of patient responses, primary and acquired resistance, as well as the management challenges of immune-related adverse events (irAEs). To achieve precise individualized immunotherapy, this review systematically summarizes the multidimensional biomarker profiles that can predict the efficacy, resistance, and safety of immunotherapy. Beyond the single PD-L1 expression, the efficacy prediction system has expanded to integrate multimodal information such as dynamic tumor microenvironment, tumor genomic characteristics, systemic inflammation/immune status, and radiomics. At the same time, studies have revealed that immune-suppressive microenvironments and specific genetic variations are key mechanisms mediating treatment resistance. Moreover, clinical characteristics, blood markers, and imaging findings provide a basis for predicting the risk of irAEs. Looking to the future, the core to overcoming current bottlenecks lies in constructing dynamic and integrated prediction models. By integrating multiomics data, longitudinal liquid biopsies, and artificial intelligence algorithms, an intelligent decision-making system is expected to be developed to achieve real-time monitoring of treatment response, early identification of resistance mechanisms, and proactive management of toxicity risks, ultimately optimizing the clinical practice of NSCLC immunotherapy and advancing it towards higher-order precision medicine.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 18","pages":"e70342"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149031362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diverging Trajectories of Lung Cancer Burden in China, Japan, and South Korea: A Comparative Risk Assessment from the Global Burden of Disease Study 1990-2021.","authors":"Siyuan Zhao, Gang Deng, Dong Li, Hongsen Liang, Di Tang, Kai Liu","doi":"10.1111/1759-7714.70370","DOIUrl":"10.1111/1759-7714.70370","url":null,"abstract":"<p><strong>Objective: </strong>Lung cancer poses a major public health challenge in East Asia. This study aimed to compare the evolving burden of lung cancer and key risk factors from 1990 to 2021 in China, Japan, and South Korea, three neighboring countries with distinct socioeconomic and public health profiles.</p><p><strong>Methods: </strong>Using data from Global Burden of Disease Study 2021, we applied an integrated analytical framework. This included Joinpoint regression to identify trend transitions, an Age-Period-Cohort model to disentangle demographic effects, and ARIMA time-series modeling for forecasting. Risk attribution and cluster analysis assessed contributions of behavioral, environmental, occupational, and metabolic factors. Marked disparities were observed.</p><p><strong>Results: </strong>China's age-standardized mortality rate (ASMR) increased (Estimated Annual Percentage Change, EAPC = +0.25%), while Japan (EAPC = -0.91%) and South Korea (EAPC = -1.02%) experienced declines. Smoking remained the predominant risk factor (Attribution score: 10/10), but risk profiles diverged: ambient air pollution contributed 9/10 to China's burden, occupational asbestos dominated in Japan (Score: 8/10), and metabolic risks (high fasting plasma glucose) rose sharply in South Korea (+18.4% since 1990). The burden peaked in the 65-79 age group, with male mortality 3-8 times higher than females. Projections suggest stabilization in China (ASMR ~30.5 by 2050), continued decline in Japan (~12.0), and a potential rebound risk in South Korea by 2050.</p><p><strong>Conclusion: </strong>Lung cancer burden reflects divergent epidemiological transitions, shaped by socioeconomic development and public health policies. Precision prevention strategies are essential, prioritizing tobacco control and air quality in China, occupational risks in Japan, and metabolic factors in South Korea, supported by regional collaboration.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 16","pages":"e70370"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13504456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148814166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights Into Genomic Drivers, Transcriptomic Heterogeneity, and Therapeutic Vulnerabilities From Novel Mesothelioma Cell Lines.","authors":"Yani Wu, Fang Cao, Jiayin Dai, Zhenli Yang, Yanli Zhu, Dongmei Lin, Xiaocui Bian, Yuqin Liu","doi":"10.1111/1759-7714.70366","DOIUrl":"10.1111/1759-7714.70366","url":null,"abstract":"<p><strong>Background: </strong>Pleural mesothelioma (PM) is an aggressive cancer with limited therapeutic options and poor prognosis, necessitating comprehensive model systems for mechanistic studies and drug discovery.</p><p><strong>Methods: </strong>Tumor cells were isolated from malignant pleural effusion of PM patients and subjected to primary culture and continuous passaging. Cell lines were successfully established after more than 40 continuous passages in vitro. Cell identification included morphological analysis, species identification, short tandem repeat (STR) profiling, mycoplasma detection, in vitro proliferation assays, in vivo tumorigenicity testing in NOD/SCID mice, and immunohistochemical characterization. Genomic landscapes and transcriptomic profiling were defined by whole-exome, whole-genome sequencing, and RNA-sequencing.</p><p><strong>Results: </strong>Three Chinese-derived pleural mesothelioma cell lines (PUMC-MESO1, PUMC-MESO3, and PUMC-MESO4) were successfully established. All three cell lines exhibited epithelioid morphology with adherent growth patterns. Upon subcutaneous transplantation into NOD/SCID mice, PUMC-MESO1 and PUMC-MESO4 demonstrated tumorigenicity, while PUMC-MESO3 remained non-tumorigenic after 3 months of observation. Histopathological examination confirmed their mesothelioma origin through positive staining for mesothelial markers including calretinin, WT-1, and D2-40. Genomic analysis revealed characteristic PM genomic alterations including mutations in BAP1, NF2, and TP53, along with CDKN2A deletions. Transcriptomic analyses revealed heterogeneous molecular features among the three cell lines. Although the PUMC-MESO cell lines displayed distinct clustering patterns relative to the CCLE mesothelioma cohort, each retained transcriptomic similarities to specific established mesothelioma models. Drug sensitivity assays further demonstrated heterogeneous responses to standard therapeutic agents.</p><p><strong>Conclusion: </strong>This study reports the establishment and characterization of three novel PM cell lines. These models recapitulate key aspects of PM biology, exhibit diverse therapeutic responses, and provide a valuable new resource for investigating disease mechanisms and advancing precision oncology research.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 15","pages":"e70366"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148670704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Noncanonical MET Exon 14 Splice-Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib.","authors":"Hyung-Joo Oh, Yoo-Duk Choi, Yoon-La Choi, Ha-Young Park, Joon-Young Yoon, Jang-Hyeon Kim, Jung-Hwan Lim, Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim","doi":"10.1111/1759-7714.70371","DOIUrl":"10.1111/1759-7714.70371","url":null,"abstract":"<p><p>MET exon 14 skipping is an actionable oncogenic driver in non-small cell lung carcinoma (NSCLC); however, noncanonical splice-region variants are frequently classified as variants of unknown significance (VUS), which may result in missed therapeutic opportunities and highlight limitations in current DNA next-generation sequencing (NGS) reporting criteria. We report a patient with pulmonary sarcomatoid carcinoma harboring a noncanonical MET splice donor-proximal indel (c.3022_3028 + 13delinsA), initially interpreted as a VUS, who achieved a rapid and durable response to capmatinib. Subsequent RNA sequencing and droplet digital PCR (ddPCR) confirmed MET exon 14 skipping, supporting the value of orthogonal transcript-level validation for exon-adjacent variants.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 15","pages":"e70371"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13451342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between Lower Lobe Dose Parameters and Radiation Pneumonitis in Definitive Radiation Therapy for Non-Small Cell Lung Cancer.","authors":"Sachiko Miura, Nobuhide Wakai, Shigeto Hontsu, Masahide Ota, Kaori Yamaki, Tetsuro Tamamoto, Masayuki Takeda, Fumiaki Isohashi","doi":"10.1111/1759-7714.70369","DOIUrl":"10.1111/1759-7714.70369","url":null,"abstract":"<p><strong>Background: </strong>This study examined whether lobar-specific dose-volume histogram (DVH) parameters add predictive information for radiation pneumonitis (RP) beyond conventional whole-lung parameters in patients with non-small cell lung cancer (NSCLC) undergoing definitive radiotherapy.</p><p><strong>Methods: </strong>We retrospectively analyzed 145 NSCLC patients treated between 2018 and 2023. Conventional whole-lung parameters, including V5%, V20%, and mean lung dose (MLD), lobar-specific parameters, including Low V20% (percentage of the bilateral lower lobes receiving ≥ 20 Gy), and clinical parameters were analyzed. The predictive performance of each parameter for Grade ≥ 2 RP was evaluated using receiver operating characteristic curve analysis. Associations with Grade ≥ 2 RP were assessed by Gray test and Fine-Gray competing risks regression.</p><p><strong>Results: </strong>Grade ≥ 2 RP had an incidence of 41% (60/145) and showed significant associations with V20% (p = 0.005), MLD (p = 0.025), Low V5% (p = 0.006), and Low V20% (p = 0.003). In multivariate analysis, a high Brinkman Index (BI) (HR = 2.10, 95% CI: 1.27-3.48, p = 0.004) and high Low V20% (HR = 2.31, 95% CI: 1.12-4.74, p = 0.023) were independent predictors for Grade ≥ 2 RP. The correlation between V20% and Low V20% was moderate (r = 0.505), with minimal multicollinearity (variance inflation factor 1.34).</p><p><strong>Conclusion: </strong>Low V20% was independently associated with Grade ≥ 2 RP and may provide complementary information to conventional whole-lung DVH parameters and BI. This simple lobar-specific parameter may help refine pretreatment RP risk stratification, although external validation is required before its incorporation into individualized planning constraints.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 16","pages":"e70369"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13487692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoker's Lungs: Quo Vadis? Exploring the Shared and Individual Smoking-Related Molecular Pathways of Emphysema, Carcinoma, and Fibrosis - An Illustrative Review.","authors":"Lovorka Grgurević, Stela Hrkač, Ruđer Novak, Grgur Salai, Joško Mitrović, Tomo Svaguša","doi":"10.1111/1759-7714.70382","DOIUrl":"10.1111/1759-7714.70382","url":null,"abstract":"<p><p>Cigarette smoking is a major preventable risk factor for the development of lung cancer and chronic obstructive pulmonary disease (COPD); furthermore, it is also associated with idiopathic pulmonary fibrosis (IPF). Cigarette smoke primarily induces chronic epithelial injury in the lungs, initiating a cascade of interconnected molecular responses within the pulmonary microenvironment. Aiming to explore the common and individual important pathways in the processes of malignant alteration (non-small cell carcinoma), lung tissue destruction (emphysema in the context of COPD), and aberrant healing (IPF), we conducted a narrative review in which we explore the roles of various selected processes, including NFκB activation, mitochondrial dysfunction, the role of reactive oxygen species, and the antioxidant response via Keap1/Nrf2 and TGFβ-mediated signaling, in the context of their respective disease. This review is not meant to represent an exhaustive reference of pathophysiologic processes involved in the pathogenesis of these diseases, but to illustrate the common features and specific differences among the selected disease processes. Given the persistent global burden of tobacco use, further research into the interconnected molecular consequences of cigarette smoke exposure remains essential for advancing both preventive and therapeutic approaches in pulmonary medicine.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 16","pages":"e70382"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13504685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148814163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decision-Support Framework for Nutritional Risk in Small Cell Lung Cancer: A Time-Series Model Using Imputation Strategies for Incomplete Clinical Data.","authors":"Ruili Pan, Yifan Zhao, Mengzhao Wang, Weida Liu, Shuo Ji, Ya Liu, Yuchen Zhang, Chenxi Ma, Minjiang Chen, Yan Xu","doi":"10.1111/1759-7714.70381","DOIUrl":"10.1111/1759-7714.70381","url":null,"abstract":"<p><p>In patients with small cell lung cancer (SCLC), nutritional status is a key determinant of disease progression, treatment tolerance, and prognosis. The prognostic nutritional index (PNI), reflecting both immune and nutritional conditions, is widely used to evaluate prognostic risk, but its longitudinal monitoring is often limited by incomplete clinical data in real-world settings. This study aimed to propose a decision-support framework for predicting future nutritional status and improving risk screening in SCLC patients with missing data. Using PNI values and related variables from the first four follow-up time points to predict the PNI at the fifth time point (PNI5) and evaluated the impact of different missing data imputation strategies on predictive performance. Missing PNI values were imputed using mean imputation, multiple imputation (MI), Kalman filtering, k-nearest neighbors (KNN), and XGBoost imputation. Predictive models were developed with two machine learning algorithms: random forest (RF) and XGBoost. The RF model demonstrated better overall performance, and MI combined with RF achieved the best predictive accuracy (MAE: 2.952; RMSE: 3.727). Predicted PNI values were further translated into risk categories using a predefined threshold (PNI = 45), with overall accuracy of 93.33%, PPV 95.24%, and NPV 92.59%. Importantly, the model enabled risk assessment in patients with incomplete laboratory data, covering previously unassessable cases and reducing monitoring gaps. This study highlights the importance of appropriate imputation strategies in and provides a practical tool for continuous nutritional risk assessment and early identification of high-risk patients in SCLC.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 16","pages":"e70381"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13504445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148814183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TLS as Predictors and Targets in Neoadjuvant Chemoimmunotherapy for NSCLC.","authors":"Zhiqi Li, Lina Zhang, Yujie Dong, Ling Yi, Weiying Li, Jinghui Wang, Yuanming Pan","doi":"10.1111/1759-7714.70375","DOIUrl":"https://doi.org/10.1111/1759-7714.70375","url":null,"abstract":"<p><p>Tertiary lymphoid structures (TLS) have emerged as critical modulators of antitumor immunity in non-small cell lung cancer (NSCLC), with growing evidence supporting their role as both prognostic biomarkers and functional targets in neoadjuvant chemoimmunotherapy. TLS are organized ectopic lymphoid aggregates that facilitate local antigen presentation, T and B cell activation, and memory immune responses within the tumor microenvironment. Their presence and maturation status correlate with favorable clinical outcomes and enhanced responsiveness to immune checkpoint inhibitors. Despite these insights, several obstacles hinder clinical translation. Current approaches remain limited in dynamically monitoring TLS evolution during treatment, and the underlying immunoregulatory mechanisms-particularly interactions among immune subsets, stromal components, and tumor cells-are not fully elucidated. Additionally, translation faces challenges including inter-institutional variability, lack of standardized assessment criteria, and the need for multi-center prospective validation. Integrating multimodal technologies-high-plex imaging, spatial transcriptomics, and digital pathology-with AI-based platforms holds promise for refined TLS characterization and real-time monitoring. Near-term priorities include optimizing dynamic monitoring techniques and establishing standardized scoring systems. Medium-to-long-term priorities encompass multi-center trials to validate TLS utility across diverse populations, identify novel drivers of TLS formation, and develop optimized combinatorial immunotherapy regimens that leverage TLS as both predictive biomarkers and therapeutic targets. By bridging basic immunology and clinical oncology, TLS are poised to emerge as key regulatory nodes in precision cancer immunotherapy, which may catalyze a paradigm shift in the neoadjuvant NSCLC landscape, enabling a closed-loop management framework encompassing prediction, intervention, and dynamic efficacy optimization across the entire continuum of patient care.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 16","pages":"e70375"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13474490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary Team Care for Early-Stage Lung Cancer in Low- and Middle-Income Countries and Emerging Economies: Current Position and Call for Action.","authors":"Luiz Henrique Araujo, Francisco J Orlandi, Adli Azam, Lucia Viola, Yasser Elkerm, Jorge Alatorre-Alexander, Sevin Başer Öncel, Gustavo A Lyons, Xiao Li, Trung Lam Quoc, Anusheel Munshi, Francisco Gonzalez","doi":"10.1111/1759-7714.70372","DOIUrl":"https://doi.org/10.1111/1759-7714.70372","url":null,"abstract":"<p><p>Lung cancer (LC) is a complex cancer marked by poor prognosis. Low- and middle-income countries (LMICs) and emerging economies have witnessed a growing burden of LC in recent years due to low symptom awareness, rising tobacco use, air pollution, and pulmonary infections. Managing LC optimally requires a multidisciplinary team (MDT) approach to support accurate diagnosis, staging, and treatment. MDT presentation has been linked to timely diagnosis and staging, receipt of surgery, and survival benefits in early-stage LC (ESLC). However, delivering high-quality ESLC care through an MDT approach remains challenging in LMICs and emerging economies. Weak organizational structure, fragmentation of the financing and health system, oncology workforce deficits, and unawareness of the potential impact of MDTs hinder optimal care. Systematic identification, analysis, and reporting of barriers to ESLC care are critical for improving care quality and informing effective corrective interventions. This article aimed to explore barriers to MDT implementation that are unique to the care of patients with ESLC in LMICs and emerging economies and developed evidence-informed recommendations for strengthening MDT care pathways. Key focus areas addressed by these recommendations include the composition of the MDT panel for ESLC management, standardizing MDT processes and guidelines, defining standardized datasets for data collection and internal MDT review, data sharing practices, and streamlining decision-making processes. This guidance document also provides a rational framework for improved standardized MDT care in ESLC (RISE-LC) to guide the implementation and optimization of MDT care in resource-constrained settings, aiming to improve timely diagnosis, treatment coordination, and patient outcomes.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 16","pages":"e70372"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13483319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}